Insider filing · VRCA

Jayson Rieger bought $2.8M of Verrica Pharmaceuticals (VRCA)

Executed Nov 22 2024, disclosed Nov 26 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 26 2024), the stock returned -34.0% (delay-adjusted); from the execution session (Nov 22 2024), -28.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

JR Jayson Rieger CEO and President profile →

Jayson Rieger (CEO and President) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in VRCA. Across 1 priced purchase filing, the average 21-session return was +73.2% from execution and +73.2% from disclosure (delay-adjusted; derived). The largest single filing was $400K of VRCA (94,311 sh × $4.24, as filed), executed Nov 25 2025.

VRCA VRCA VRCA · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→